Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
CAR T‐cell expansion after idecabtagene vicleucel is a predictor of outcomes in myeloma, with responder patients exhibiting significantly higher peak CAR T‐cell values and better persistence.”
Title: CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma
Authors: Benoît Ferment, Amani Ouedrani, Alexis Talbot, Naouel Mouri, Pauline Zarnitzky, Romain Stammler, Tristan Vaugeois, Antoine Diep, Stéphanie Harel, Bruno Royer, Floriane Theves, Nathalie Forgeard, Vincent Allain, Sophie Caillat-Zucman, Bertrand Arnulf
You can read the Full Article on HemaSphere.
You can find other articles featuring Robert Orlowski on OncoDaily.
